Article

Busulfan and Subsequent Malignancy: An Evidence-Based Risk Assessment

2023-08-21

Abstract excerpt

The incidence of secondary malignancies associated with busulfan exposure is considered low, but has been poorly characterized. Because this alkylating agent is increasingly utilized as conditioning prior to gene therapy in non-malignant hematologic and related disorders, more precise characterization of busulfan’s potential contribution to subsequent malignant risk is warranted. We conducted a literature-based as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 30d16f19-1136-5af0-a84a-8be41dab3fe9
DOI: 10.22541/au.169259765.51803663/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Busulfan and Subsequent Malignancy: An Evidence-Based Risk AssessmentDOI 10.22541/au.169259765.51803663/v1Read

Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell diseaseSemantic proximity Read

Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioningSemantic proximity Read

Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.Semantic proximity Read

Therapy-related myeloid neoplasms: when genetics and environment collide.Semantic proximity Read

Malignancies After Hematopoietic Stem Cell Transplantation: Many Questions, Some AnswersSemantic proximity Read

Therapy-related myelodysplasia and acute myeloid leukemia.Semantic proximity Read

Subsequent Cancers following Non-myeloablative Conditioning for Allogeneic Hematopoietic Cell TransplantationSemantic proximity Read

Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neitherSemantic proximity Read

Cancer spectrum and outcomes in the Mendelian short telomere syndromesSemantic proximity Read

GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.Semantic proximity Read

Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.Semantic proximity Read

GSTM1 and GSTT1 Double Null Genotypes Determining Cell Fate and Proliferation as Potential Risk Factors of Relapse in Children With Hematological Malignancies After Stem Cell Transplantation. On Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow TransplantationSemantic proximity Read